China’s next drug-price reset runs on provincial clocks
Fujian’s new notice and Beijing’s rollout show separate price, procurement and payment switches. The 70% payment-standard rule also needs a floor—not a reimbursement shortcut.
Desk analysis
Deeper reads on regulation or deals.
Charles River’s $470m Frontage purchase hinges on a take-private and a split
The proposed deal would take Frontage private before allocating its businesses to Charles River, Tigermed and Song Li. The $470m price covers the target operations.
TYK is paying RMB 300 million so Qilu can sell a drug Huiyu says it already had.
TYK Medicines will pay Huiyu RMB 300m—the same cash Qilu put up as an upfront—to end a fight over who may sell TY-9591 in mainland China. Qilu’s field activity is dated 13 November.
Reading China’s TGCT market through Beijiemai: hospitals first, reimbursement still open
China approved Beijiemai first, Merck sells it, hospitals wrote the first Rxs—while list price and NRDL remain the open China-market questions behind today’s FDA headline.
Abbisko’s pimicotinib at FDA: reading the China-to-Merck path
FDA approval is the headline; the BD story is the staged Merck license—$70m upfront, $85m global option, up to $605.5m total, plus a $20m U.S. first-sale milestone.